All In Biotech

Drug Trial Radar · NCT00542412

CARE Canadian ALS Riluzole Evaluation

Care (Canadian ALS Riluzole Evaluation) Multicentre Phase IV Comparative Study of the Effects of Riluzole 50mg Bid on the Survival of ALS Subjects Compared to Historical Controls

Last checked: Nov 20, 2026Latest source record: Oct 11, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

414

Actual

Start

Jan 2001

Primary completion

Not stated

Study completion Dec 2004

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Oct 11, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the efficacy of riluzole 50-mg bid defined by comparing the percentage of riluzole-treated subjects who experienced death, permanently assisted ventilation (PAV) or tracheostomy, to a group of recent historical controls for the treatment of amyotrophic lateral sclerosis (ALS).

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • RiluzoleDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary efficacy endpoint was the time to the occurrence of an ALS-related event (PAV, tracheostomy or ALS-related death)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sanofi-Aventis

    Laval, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.